Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

• US 20090110670A1
• Filed: 12/03/2008
• Published: 04/30/2009
• Est. Priority Date: 10/07/2002
• Status: Active Grant

• Current Assignee: Biogaia AB
• Original Assignee: Biogaia AB
• Inventors: Mollstam, Bo, Connolly, Eamonn
• Granted Patent: US 7,678,553 B2
• Time in Patent Office: Days
• US Class Current: 424/93.450
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A23V 2200/3204 Probiotics, living bacteria to be ingested for action in the digestive tract
• CPC Class Codes: A23V 2400/173 Reuteri
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/06 Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12P 21/00 Preparation of peptides or proteins single cell protein C12N1/00
• CPC Class Codes: C12R 2001/225 Lactobacillus

Abstract

Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.

Claims

1-23. -23. (canceled)

24. A method for selecting a lactic acid bacterial strain for administration to a mammal for reducing gastrointestinal inflammation associated with Helicobacter pylori infection in the gastrointestinal tract of said mammal, comprising the steps of:

a) selecting and culturing a Lactobacillus strain;

b) obtaining a cell-free culture supernatant from said strain; and

c) evaluating the level of TNFα

in the supernatant using a model system

25. A strain of Lactobacillus selected by the method of claim 24.

26. The strain of Lactobacillus of claim 25, wherein said strain is selected from the group consisting of MM2-3, ATCC PTA-4659 and Lactobacillus coryniformis strain MM7, ATCC PTA-4660.

27. A cell-free culture supernatant isolated from a Lactobacillus strain selected by the method of claim 24.

28. The cell-free culture supernatant of claim 27, wherein said strain is selected from the group consisting of MM2-3, ATCC PTA-4659 and Lactobacillus coryniformis strain MM7, ATCC PTA-4660.

29. A Helicobacter pylori associated inflammation-reducing component derived from a strain of Lactobacillus selected by the method of claim 24, wherein said component is obtained from a cell-free culture supernatant according to claim 27 and has the capability of reducing the level of TNFα

.

30. The Helicobacter pylori associated inflammation-reducing component of claim 29, wherein said strain is selected from the group consisting of MM2-3, ATCC PTA-4659 and Lactobacillus coryniformis strain MM7, ATCC PTA-4660.

31. The Helicobacter pylori associated inflammation-reducing component of claim 29, wherein said component is a protein or part thereof.

32. The Helicobacter pylori associated inflammation-reducing component according to claim 31, wherein the protein, or part thereof, is characterized by being smaller than 5 kDa.

33. A food composition comprising an ingestible support and the Helicobacter pylori associated inflammation-reducing component according to claim 29.

34. A pharmaceutical composition comprising a pharmaceutical carrier and a Helicobacter pylori associated inflammation-reducing component according to claim 29.

35. The pharmaceutical composition of claim 34, wherein said strain is selected from the group consisting of MM2-3, ATCC PTA-4659 and Lactobacillus coryniformis strain MM7, ATCC PTA-4660

36. A nutritional supplement comprising an ingestible support and a Helicobacter pylori associated inflammation-reducing component according to claim 29.

37. The nutritional supplement of claim 36, wherein said strain is selected from the group consisting of MM2-3, ATCC PTA-4659 and Lactobacillus coryniformis strain MM7, ATCC PTA-4660.

38. An agent for treatment or prophylaxis of inflammation associated with Helicobacter pylori, comprising the Helicobacter pylori associated inflammation-reducing of claim 29.

39. The agent of claim 38, wherein said strain is selected from the group consisting of MM2-3, ATCC PTA-4659 and Lactobacillus coryniformis strain MM7, ATCC PTA-4660